Analysts Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) PT at $16.20

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been assigned an average rating of “Reduce” from the seven brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $17.1667.

Several analysts recently weighed in on IART shares. BMO Capital Markets began coverage on Integra LifeSciences in a report on Wednesday. They issued a “market perform” rating and a $19.00 price objective for the company. Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Citigroup reaffirmed a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday. Truist Financial reduced their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Finally, Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th.

Integra LifeSciences Trading Up 2.2%

IART stock traded up $0.40 during mid-day trading on Friday, reaching $18.79. The company had a trading volume of 951,870 shares, compared to its average volume of 893,598. The company has a market capitalization of $1.46 billion, a PE ratio of -2.91, a price-to-earnings-growth ratio of 1.30 and a beta of 1.22. The firm has a 50 day moving average of $16.32 and a 200 day moving average of $12.86. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $18.92. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.Integra LifeSciences’s revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Osaic Holdings Inc. boosted its stake in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares in the last quarter. State of Tennessee Department of Treasury increased its stake in shares of Integra LifeSciences by 7.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after purchasing an additional 1,964 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares during the period. Capital Fund Management S.A. boosted its position in Integra LifeSciences by 5.7% during the third quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after purchasing an additional 1,997 shares in the last quarter. Finally, Global Retirement Partners LLC purchased a new position in Integra LifeSciences during the fourth quarter worth approximately $25,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.